Samsung Biologics to help Enzolytics advance clinical development of mAbs

By Jane Byrne contact

- Last updated on GMT

© GettyImages/Naeblys
© GettyImages/Naeblys

Related tags: Monoclonal antibodies, COVID-19, Hiv

Samsung Biologics and Enzolytics have entered into a strategic CDMO partnership agreement targeting monoclonal antibody production.

The financial terms of the deal were not disclosed.

Texas based biotechnology company, Enzolytics Inc, is to leverage the contract development and manufacturing organization's expertise to advance both anti-HIV and anti-SARS-CoV-2 monoclonal antibody therapies to IND.

Samsung will provide a seamless, end-to-end CDMO service with support from its San Francisco R&D Center including cell line development, clinical drug substance, and drug product manufacturing services. Related clinical trial materials will be manufactured at its headquarters in Incheon, South Korea.

In addition, the partners will discuss potentially working on other monoclonal antibodies (mAbs) being developed by that drug development company.

Dr Gaurav Chandra, COO, research and development, Enzolytics, said the company chose to partner with Samsung because of the CDMO’s extensive experience and expertise in developing, producing, and manufacturing infectious diseases and oncology targeted mAbs.

“This partnership marks a pivotal milestone for Enzolytics to significantly advance the clinical development of our universal, durable, broadly neutralizing monoclonal antibodies and reduce time to the clinic and offer the much-needed treatment for patients."

Mulitiple infectious disease targets

The Enzolytics mAb platform is based on AI, and is said to enable the creation of multiple fully human mAbs targeting conserved immutable sites on the virus.

Besides HIV and coronavirus, Enzolytics is looking to treat HTLV-1, Influenza A, and B, H10N3, H1N1 influenza, Respiratory syncytial virus (RSV), Ebola, Small-Pox, Herpes zoster, Varicella zoster, Elephant endotheliotropic herpesviruses, Feline Leukemia Virus, Equine Infectious Anemia Virus, and Koala retrovirus.

Enzolytics acquired the mAb technology targeting HIV and COVID-19 following its acquisition last year of BioClonetics Immunotherapeutics. Enzolytics’ flagship compound is ITV-1, a suspension of Inactivated Pepsin Fragment (IPF); studies have shown the compound is effective in the treatment of HIV, reported the US biotech.

Related news

Show more

Related products

show more

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 10-Feb-2021 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Rapid Biosafety Testing Enables the Future of Manufacturing

Rapid Biosafety Testing Enables the Future of Manufacturing

Viral Safety for mAb: Prevent, Detect, Remove | 23-Nov-2020 | Technical / White Paper

This white paper explores the factors driving the evolution toward faster biosafety testing and describes rapid approaches for adventitious agent testing...

Related suppliers

Follow us

Products

View more

Webinars